

OPKOCONNECT

ACCESS AND REIMBURSEMENT SUPPORT

INSIDE:
Key Resources for
Healthcare Provider
Offices and Patients



VISIT US ONLINE AT www.Royaldee.com



OR CALL **1-844-414-OPKO (6756)**
to speak with one of our Royaldee®
Care Managers **Monday through Friday**
from 8am-8pm ET

OPKO CONNECT

PROVIDES COMPREHENSIVE SUPPORT


**Partnering with patients and their care team
to gain affordable access to Rayaldee® (calcifediol)
extended-release 30 mcg capsules**

As part of our commitment to positively impacting lives, OPKO Renal is pleased to offer OPKO Connect, a centralized resource dedicated to helping patients access Rayaldee® as quickly and as easily as possible.

OPKO Connect will help:

- Verify prescription insurance coverage for the patient
- Assist with insurance required Prior Authorizations
- Obtain copay assistance for the patient
- Minimize time to Rayaldee therapy initiation and contact patients to help maintain adherence to therapy





For your convenience,
additional information and
program resources are
available both online
and by phone:



VISIT US ONLINE AT
www.Royaldee.com



OR CALL 1-844-414-OPKO (6756) to speak
with one of our Royaldee® Care Managers
Monday through Friday from 8am-8pm ET



GENERAL SUPPORT

OPKO Connect will provide general support services such as:

- Assisting patients, caregivers, healthcare provider offices, and pharmacies with **product or program questions**
- Assisting patients, caregivers, and healthcare provider offices with **insurance coverage questions**
- Obtaining copay support or financial assistance for patients
- Resolving claims submission issues on behalf of patients



BENEFITS INVESTIGATION SUPPORT

OPKO Connect will **assist with investigating** a patient's insurance coverage and **benefit design** for Rayaldee® (calcifediol) extended-release 30 mcg capsules.

Our Rayaldee® Care Managers will verify:

- **Prior Authorization (PA)** requirements
- **Patient deductibles** and out-of-pocket costs
- **Alternative insurance coverage that may be available to patients,** such as Medicare, Medicaid, and the low-income subsidy (LIS) program

To receive this support for your patients, please complete the Rayaldee® Service Request Form (SRF) provided on the OPKO Connect Resources page at www.rayaldee.com/hcp-financial-support/ and fax it to us at **1-844-660-7083** or email to opkoconnect@rxallcare.com.




PRIOR AUTHORIZATION SUPPORT

OPKO Connect will **assist with insurer-required prior authorizations** (PAs) for Rayaldee® (calcifediol) extended-release 30 mcg capsules.

Rayaldee® Care Managers will provide support with:

- Supplying insurer-specific PA forms to the healthcare provider's office with instructions on how to complete and submit the form to the insurer
- Confirming receipt of PA submission with the insurer to help facilitate a timely review
- Contacting the patient and their healthcare provider's office to confirm status
- Determining appeals option if the PA is denied





APPEALS SUPPORT

OPKO Connect will **assist with the appeals process** if a PA is denied by the insurer.

Royaldee® Care Managers will provide support with:

- Confirming the reason for the PA denial
- Supplying a Royaldee letter of medical necessity template (appeal) to the healthcare provider's office with instructions on how to complete and submit the appeal to the insurer
- Confirming receipt of appeal submission with the insurer to help facilitate a timely review
- Contacting the patient and their healthcare provider's office to confirm status
- Determining Patient Assistance Program (PAP) option if the appeal is denied



COPAY ASSISTANCE PROGRAM

Eligible commercially insured patients can fill their Royaldee prescription for **\$0 with eVoucherRx™**, a program from RelayHealth that **automatically applies copay savings at the patient's pharmacy.**

If the patient's pharmacy is not in the RelayHealth **eVoucherRx™** network, then **OPKO Connect will provide the pharmacy a copay card that automatically applies the \$0 copay at the pharmacy for eligible commercially insured patients.**

Contact OPKO Connect at 1-844-414-OPKO (6756) with any questions.



PATIENT ASSISTANCE PROGRAM (PAP)

For patients that do not have insurance coverage or are unable to afford their Rayaldee copay, OPKO offers a **free drug patient assistance program**; eligibility criteria apply and annual re-enrollment is required.

In order to determine a patient's eligibility for this program:

- The healthcare provider's office must submit a completed Service Request Form (SRF) to OPKO Connect by fax at **1-844-660-7083** or email to opkoconnect@rxallcare.com
 - If an SRF was previously submitted prior to identifying the need for patient assistance, a new form is not required from the healthcare provider office
- Rayaldee® must be prescribed for on-label usage
- Upon receipt of the SRF or upon identifying the need for patient assistance, OPKO Connect will contact the patient to obtain a completed PAP application and the necessary supporting financial documentation
- Once a determination has been made regarding eligibility, OPKO Connect will contact the patient and their healthcare provider's office to confirm status

FOR MORE INFORMATION ABOUT AVAILABLE SERVICES AND TO ACCESS PROGRAM RESOURCES



VISIT US ONLINE AT www.Royaldee.com



OR CALL 1-844-414-OPKO (6756)
to speak with one of our Rayaldee®
Care Managers **Monday through Friday**
from 8am-8pm ET



Royaldee is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Royaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.

- **Hypercalcemia:** Excessive administration of vitamin D compounds, including Royaldee, can cause hypercalcemia and hypercalciuria. Severe hypercalcemia due to substantial overdosage of vitamin D and its metabolites may require emergency attention. Patients should be informed about the symptoms of elevated calcium.
- **Digitalis toxicity:** Potentiated by hypercalcemia of any cause. Monitor serum calcium and signs and symptoms of digitalis toxicity more frequently when initiating or adjusting the dose of Royaldee.
- **Adynamic Bone Disease:** Monitor for abnormally low levels of intact PTH levels when using Royaldee and adjust dose if needed.
- The most common adverse reactions ($\geq 3\%$ and more frequent than placebo) were anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation.
- Care should be taken while dosing Royaldee with cytochrome P450 inhibitors, thiazides, cholestyramine or drugs stimulating microsomal hydroxylation due to the potential for drug interactions.
- Serum calcium should be below 9.8 mg/dL before initiating treatment.
- Monitor serum calcium, phosphorus, 25-hydroxyvitamin D and intact parathyroid hormone (iPTH) 3 months after starting therapy or changing dose.

Please see accompanying Full Prescribing Information or view at www.Royaldee.com



NOTES

[illegible]

NOTES

This image shows a full page of blank, lined paper. It features approximately 20 evenly spaced horizontal grey lines across its entire width, providing a guide for handwriting or typing. The paper itself is a clean, off-white color. There are no margins, text, or other markings present on the page.



OPKOCONNECT

PROVIDES COMPREHENSIVE SUPPORT

As part of our commitment to positively impacting lives, OPKO Renal, a division of OPKO Health, Inc., is pleased to offer OPKO Connect, a centralized resource dedicated to helping patients access Rayaldee® (calcifediol) extended-release 30 mcg capsules as quickly and as easily as possible.

OPKO Connect will help with:

- General Support
- Benefits Investigation Support
- Prior Authorization Assistance
- Appeals Support
- Copay Assistance
- Patient Assistance Programs (PAP)



VISIT US ONLINE AT www.Rayaldee.com



OR CALL 1-844-414-OPKO (6756)
to speak with one of our Rayaldee®
Care Managers **Monday through Friday**
from 8am-8pm ET

OPKORENAL

Rayaldee® is a registered trademark of Eirgen Pharma Ltd. OPKO Renal is a division of OPKO Health, Inc.
© 2023 OPKO Pharmaceuticals, LLC. All rights reserved OP-US-0033-052023v.4